NCT01378117: Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes |
|
|
| Completed | 4 | 90 | US | Sitagliptin, Januvia, glargine, Lantus (glargine), lispro, Humalog (lispro) | Emory University, Merck Sharp & Dohme LLC | Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia | 05/12 | 06/12 | | |
NCT01845831: Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes |
|
|
| Completed | 4 | 292 | US | Sitagliptin, Januvia, Basal Bolus, Glargine (Lantus) + aspart (Novolog) or lispro (Humalog), Metformin and Sitagliptin, Janumet, Glargine, Lantus, Glargine 50%, Glargine 80% | Emory University, Merck Sharp & Dohme LLC, Temple University, University of Michigan, Ohio University | Type 2 Diabetes | 04/16 | 04/16 | | |
